In preclinical studies, the combination of ICIs, such as anti-PD-1/PD-L1, with EGFR blockers has been found to improve the efficacy of ICIs in NSCLC and CRC [172,173,174]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.